PharmaEssentia Corporation
6446
株式のランク
#1418
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
株価
$37.84
時価総額
$15.65B
変化（1日）
-4.42%
変化（1年）
149.23%
国
TW
取引 PharmaEssentia Corporation (6446)
カテゴリー
Healthcare
PharmaEssentia Corporation（6446）のEPS
June 2026 時点のEPS TTM: $0.63
PharmaEssentia Corporationの最新の財務報告と株価によると、同社の現在のEPS（TTM）は$0.63です。2023年末には、EPSは$-0.06で、2022年のEPS$-0.14と減少でした。
PharmaEssentia CorporationのEPS履歴（2010から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $0.63 | 153.00% |
| 2024 | $0.25 | -534.22% |
| 2023 | $-0.06 | -60.15% |
| 2022 | $-0.14 | -59.50% |
| 2021 | $-0.35 | 37.91% |
| 2020 | $-0.25 | 119.47% |
| 2019 | $-0.12 | -14.95% |
| 2018 | $-0.14 | 15.09% |
| 2017 | $-0.12 | 5.89% |
| 2016 | $-0.11 | -6.67% |
| 2015 | $-0.12 | -4.08% |
| 2014 | $-0.13 | 25.60% |
| 2013 | $-0.10 | 63.82% |
| 2012 | $-0.06 | 25.36% |
| 2011 | $-0.05 | 16.87% |
| 2010 | $-0.04 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -12.05% |
IN
|
